Flap opening and dimer-interface flexibility in the free and inhibitor- bound HIV protease, and their implications for function

Structure

Volumn 7, Issue 9, 1999, Pages 1047-1055

  Ishima, Rieko ^a   Freedberg, Darón I ^b   Wang, Yun Xing ^a   Louis, John M ^a   Torchia, Dennis A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Chemical exchange; Dynamics; NMR; Protein; Relaxation

Indexed keywords

PROTEINASE;

ARTICLE; CONFORMATIONAL TRANSITION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME CONFORMATION; ENZYME MECHANISM; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 0033200247     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(99)80172-5     Document Type: Article

References (55)

1. 1. Oroszlan, S. & Luftig, R.B. (1990). Retroviral proteinases. Curr. Top. Microbiol. Immunol. 157, 153-185.
2. 2. Walsh, J.C., Jones, C.D., Barnes, E.A., Gazzard, B.G. & Mitchell, S.M. (1998). Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 12, 613-618.
3. 3. Condra, J. H. (1998). Resistance to HIV protease inhibitors. Haemophilia 4, 610-615.
4. 4. Weber, I.T. (1990). Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. J. Biol. Chem. 265, 10492-10496.
5. 5. Hong, L., Treharne, A., Hartsuck, J.A., Foundling, S. & Tang, J. (1996). Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases. Biochemistry 35, 10627-10633.
6. 6. Lam, P.Y., et al., & Hodge, C.N. (1996). Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2′ structure-activity relationship, and molecular recognition of cyclic ureas. J. Med. Chem. 39, 3514-3525.
7. 7. Erickson, J.W. & Burt, S.K. (1996). Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36, 545-571.
8. 8. Rose, R.B., Craik, C.S. & Stroud, R.M. (1998). Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 37, 2607-2621.
9. 9. Liu, H., Muller-Plathe, F. & van Gunsteren, W.F. (1996). A combined quantum/classical molecular dynamics study of the catalytic mechanism of HIV protease. J. Mol. Biol. 261, 454-469.
10. 10. Harte, W.E. Jr, Swaminathan, S., Mansuri, M.M., Martin, J.C., Rosenberg, I.E. & Beveridge, D.L. (1990). Domain communication in the dynamical structure of human immunodeficiency virus 1 protease. Proc. Natl Acad. Sci. USA 87, 8864-8868.
11. 11. York, D.M., Darden, T.A., Pedersen, L.G. & Anderson, M.W. (1993). Molecular dynamics simulation of HIV-1 protease in a crystalline environment and in solution. Biochemistry 32, 1443-1453.
12. 12. Collins, J.R., Burt, S.K. & Erickson, J.W. (1995). Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics. Nat. Struct. Biol. 2, 334-338.
13. 13. Rick, S.W., Erickson, J.W. & Burt, S.K. (1998). Reaction path and free energy calculations of the transition between alternate conformations of the HIV-1 protease. Proteins 32, 7-16.
14. 14. Furfine, E.S., D'Souza, E., Ingold, K.J., Leban, J.J., Spector, T. & Porter, D.J. (1992). Two-step binding mechanism for HIV protease inhibitors. Biochemistry 31, 7886-7891.
15. 15. Rodriguez, E.J., Debouck, C., Deckman, I.C., Abu-Soud, H., Raushel, F.M. & Meek, T.D. (1993). Inhibitor binding to the Phe53Trp mutant of HIV-1 protease promotes conformational changes detectable by spectrofluorometry. Biochemistry 32, 3557-3563.
16. 16. Luque, I., Todd, M.J., Gomez, J., Semo, N. & Freire, E. (1998). Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis. Biochemistry 37, 5791-5797.
17. 17. Nicholson, L.K., et al., & Jadhav, P.K. (1995). Flexibility and function in HIV-1 protease. Nat. Struct. Biol. 2, 274-280.
18. 18. Freedberg, D.I., et al., & Torchia, D.A. (1998). Flexibility and function in HIV protease - dynamics of the HIV-1 protease bound to the asymmetric Inhibitor kynostatin 272 (KNI-272). J. Am, Chem. Soc. 120, 7916-7923.
19. 19. Mildner, A.M., et al., & Tomasselli, A.G. (1994). The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry 33, 9405-9413.
20. 20. Szeltner, Z. & Polgar, L. (1996). Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration. J. Biol. Chem. 271, 5458-5463.
21. 21. Akke, M. & Palmer, A.G. (1996). Monitoring macromolecular motions on microsecond-millisecond timescales by R1rho-R1 constant-relaxation-time NMR spectroscopy. J. Am. Chem. Soc. 118, 911-912.
22. 22. Mulder, F.A.A., van Tilborg, P.J.A., Kaptein, R. & Boelens, R. (1998). Microsecond timescale dynamics in RXR DNA binding domain from a combination of spin-echo and off-resonance rotating frame relaxation measurements. J Biomol. NMR 13, 275-288.
23. 23. Ishima, R., Wingfield, P.T., Stahl, S.J., Kaufman, J.D. & Torchia, D.A. (1998). Using amide 1H and 15N transverse relaxation to detect millisecond time-scale motions in perdeuterated proteins: application to HIV-1 protease. J. Am. Chem. Soc. 120, 10534-10542.
24. 24. Yamazaki, T., et al., & Lam, P.Y. (1996). Three-dimensional solution structure of the HIV-1 protease complexed with DMP323, a novel cyclic urea-type inhibitor, determined by nuclear magnetic resonance spectroscopy. Protein Sci. 5, 495-506.
25. 25. Rose, J.R., Salto, R. & Craik, C.S. (1993). Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J. Biol. Chem. 268, 11939-11945.
26. 26. Wondrak, E.M., Nashed, N.T., Haber, M.T., Jerina, D.M. & Louis, J.M. (1996). A transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of maturation. J. Biol. Chem. 271, 4477-4481.
27. 27. Louis, J.M., Nashed, N.T., Parris, K.D., Kimmel, A.R. & Jerina, D.M. (1994). Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein., Proc. Natl Acad. Sci. USA 91, 7970-7974.
28. 28. Cherry, E., et al., & Wainberg, M.A. (1988). Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. J. Mol. Biol. 284, 43-56.
29. 29. Lapatto, R., et al., & Hobart, P.M. (1989). X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature 342, 299-302.
30. 30. Wlodawer, A., et al., & Kent, S.B. (1989). Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245, 616-621.
31. 31. Spinelli, S., Liu, Q.Z., Alzari, P.M., Hirel, P.H. & Poljak, R.J. (1991). The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochimie 73, 1391-1396.
32. 32. Chen, Z., et al., & Kuo, L.C. (1994). Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J. Biol. Chem. 269, 26344-26348.
33. 33. Lin, Y., et al., & Tang, J. (1995). Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry 34, 1143-1152.
34. 34. Moody, M.D., et al., & Swanstrom, R. (1995). A side chain at position 48 of the human immunodeficiency virus type-1 protease flap provides an additional specificity determinant. Virology 207, 475-485.
35. 35. Shao, W., Everitt, L., Manchester, M., Loeb, D.D., Hutchison, C.A. III & Swanstrom, R. (1997). Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants., Proc. Natl Acad. Sci. USA 94, 2243-2248.
36. 36. Tozser, J., et al., & Oroszlan, S. (1997). Activity of tethered human immunodeficiency virus 1 protease containing mutations in the flap region of one subunit. Eur. J. Biochem. 244, 235-241.
37. 37. Baldwin, E.T., et al., & Erickson, J.W. (1995). Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure 3, 581-590.
38. 38. Gellman, S.H. (1991). On the role of methionine residues in the sequence-independent recognition of nonpolar protein surfaces. Biochemistry 30, 6633-6636.
39. 39. Wang, Y.X., et al., & Torchia, D.A. (1996). Bound water molecules at the interface between the HIV-1 protease and a potent inhibitor, KNI-272, determined by NMR. J. Am. Chem. Soc. 118, 12287-12290.
40. 40. Wondrak, E.M. & Louis, J.M. (1996). Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. Biochemistry 35, 12957-12962.
41. 41. Weber, I.T., et al., & Louis, J.M. (1997). Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate-interactions with frequently occurring glutamic acid residue at P2′ position of substrates. Eur. J. Biochem. 249, 523-530.
42. 42. Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J. & Bax, A. (1995). NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277-293.
43. 43. Davis, D.G., Perlman, M.E. & London, R.E. (1994). Direct measurements of the dissociation-rate constant for inhibitor-enzyme complexes via the T1rho and T2(CPMG) methods. J. Magn. Reson. B 104, 266-275.
44. 44. Ross, A., Czisch, M. & King, G.C. (1997). Systematic errors associated with the CPMG pulse sequence and their effect on motional analysis of biomolecules. J. Magn. Reson. 124, 355-365.
45. 45. Luz, Z. & Meiboom, S. (1963). Nuclear magnetic resonance study of the protolysis of trimethylammonium ion in aqueous solution - order of the reaction with respect to solvent. J. Chem. Phys. 39, 366-370.
46. 46. Goldman, M. (1984). Interference effects in the relaxation of a pair of unlike spin-1/2 nuclei. J. Magn. Reson. 60, 437-452.
47. 15N NMR spectroscopy. Eur. J. Biochem. 219, 887-896.
48. 48. Allerhand, A. & Gutowsky, H.S. (1965). Spin-echo studies of chemical exchange. II. Closed formulas for two sites. J. Chem. Phys. 42, 1587-1598.
49. 49. Bloom, M., Reeves, L.W. & Wells, E.J. (1965). Spin echoes and chemical exchange. J. Chem. Phys. 42, 1615-1624.
50. 50. Carver, J.P. & Richards, R.E. (1972). A general two-site solution for the chemical exchange produced dependence of T2 upon Carr-Purcell pulse separation. J. Magn. Reson. 6, 89-105.
51. 51. Mandel, A.M., Akke, M. & Palmer, A.G. III (1996). Dynamics of ribonuclease H: temperature dependence of motions on multiple timescales. Biochemistry 35, 16009-16023.
52. 52. Schurr, J.M., Babcock, H.P. & Fujimoto, B.S. (1994). A test of the model-free formulas. Effects of anisotropic rotational diffusion and dimerization. J. Magn. Reson. B 105, 211-224
53. 53. Beeser, S.A., Goldenburg, D.P. & Oas, T.G. (1997). Enhanced protein flexibility caused by a destabilizing amino acid replacement in BPTI. J. Mol. Biol. 269, 154-164.
54. 54. Wishart, D.S., Sykes, B.D. & Richards, F.M. (1991). Relationship between nuclear magnetic resonance chemical shift and protein secondary structure. J. Mol. Biol. 222, 311-333.
55. 55. Walling, A.E., Pargas, R.E. & de Dios, A.C. (1997). Chemical shift tensors in peptides: a quantum mechanical study. J. Phys. Chem. A 101, 7299-7303.